PAVmed (PAVM) Stock Price

PAVmed Price

NASDAQ·CLOSED
1.63
​
Market closed

Revenue at PAVmed has contracted by 38.6% per year over the past 4 years to 71,000.00 USD. PAVmed's net margin stands at 564.8%, up from -10,069.4% several years earlier. Analysts set a median price target of 4.08 USD, implying 150.3% above the current price. Of 9 analysts, 7 rate the stock a buy — an overall Buy consensus.

PAVmed stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PAVmed business model & stock analysis

PAVmed, Inc. generates revenue through the development and commercialization of medical devices including PortIO, a vascular access device without central venous system access or indwelling intravascular components, and CarpX, a percutaneous device for carpal tunnel syndrome treatment. The company also offers NextCath, a self-anchoring catheter eliminating the need for suturing or traditional anchoring methods, and DisappEAR, antibiotic-eluting resorbable ear tubes utilizing aqueous silk technology. Additional products include NextFlo, a disposable infusion system with variable flow resistors, and Caldus, a disposable tissue ablation device. Medical device companies and healthcare providers purchase these products for patient treatment and surgical procedures. The firm's product portfolio targets specific medical needs such as vascular access, orthopedic procedures, and ear treatments. PortIO serves patients requiring long-term vascular access without traditional central line risks. CarpX addresses carpal tunnel syndrome through minimally invasive procedures. DisappEAR provides a solution for ear tube insertion using resorbable technology, reducing the need for follow-up surgeries. NextCath streamlines catheter placement in medical settings. PAVmed's commercial strategy focuses on medical device companies and healthcare providers seeking innovative solutions for vascular access, orthopedic interventions, and ear care. The company's products are designed to improve patient outcomes while reducing procedural complexity and costs. By leveraging proprietary technologies like aqueous silk for DisappEAR, PAVmed differentiates its offerings in the medical device market.

Frequently asked questions about PAVmed

8 analysts currently rate the PAVmed stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect PAVmed to generate revenue of 232,500.00 USD and earnings per share of -3.01 USD.

Converted at the current exchange rate, the PAVmed share trades at 1.48 EUR (1.63 USD).

The PAVmed share (PAVM) is listed on 3 stock exchanges, including: NASDAQ (PAVMZ), Frankfurt (1P5.F), Düsseldorf (1P5.DU).

The expected revenue of PAVmed is 232,500.00 USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of PAVmed is -2.33 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of PAVmed is currently -0.54. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the PAVmed stock.

The price-to-sales ratio (P/S) of PAVmed is currently 5.42. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the PAVmed stock.

The Eulerpool Quality Score for PAVmed is 4/10.

The ISIN of PAVmed is US70387R5028. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of PAVmed is A2AQDJ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of PAVmed is PAVM. The ticker symbol is used to trade PAVmed shares on the stock exchange.

Fair ValueTerminal
1.43 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
1,731.71 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website pavm.com
Currency
USD
Initial public offering
Jul 27, 2016
ISIN
US70387R5028
Cusip
70387R106
Sedol
BDC6H83
Market capitalization
1.63 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-0.54
P/Ee 2027
-0.53
P/Se
5.42
EV/EBIT
—
P/B Ratio
0.05
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
0.85 %
Last updated Nov 17, 2026, 3:51 AM

PAVmed Ticker

DÜSSELDORF · 1P5.DUFRANKFURT · 1P5.FNASDAQ · PAVMZ

All fundamentals and in-depth analysis of PAVmed

Our stock analysis for PAVmed stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PAVmed. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.